409.90 -3.20 (-0.77%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
408.0
Today’s High
414.05
52 Week Low
319.4
52 Week High
487.0
408.95 -4.50 (-1.09%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
408
Today’s High
414.35
52 Week Low
319
52 Week High
486.85
Key Metrics
- Market Cap (In Cr) 42057.08
- Beta 0.43
- Div. Yield (%) 0.6
- P/B 2.5
- TTM P/E 17.85
- Peg Ratio 2.22
- Sector P/E 27.18
- D/E 0.15
- Open Price 411.15
- Prev Close 413.1
Analysis
Price Analysis
-
1 Week3.33%
-
3 Months12.69%
-
6 Month14.4%
-
YTD-14%
-
1 Year-9.78%
Risk Meter
- 26% Low risk
- 26% Moderate risk
- 26% Balanced Risk
- 26% High risk
- 26% Extreme risk
Recos
30 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 2
- Sell
- 3
- Hold
- 11
- Buy
- 10
- Strong Buy
- 4
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 15265.2
- Selling/ General/ Admin Expenses Total
- 5385.9
- Depreciation/ Amortization
- 713
- Other Operating Expenses Total
- 288.4
- Total Operating Expense
- 12523.1
- Operating Income
- 2742.1
- Net Income Before Taxes
- 2838.1
- Net Income
- 4487.3
- Diluted Normalized EPS
- 21.01
- Period
- 2022
- Total Assets
- 27795.4
- Total Liabilities
- 10795.8
- Total Equity
- 16999.6
- Tangible Book Valueper Share Common Eq
- 102.64
- Period
- 2022
- Cashfrom Operating Activities
- 2078.2
- Cashfrom Investing Activities
- 1154.4
- Cashfrom Financing Activities
- -868.3
- Net Changein Cash
- 2372.9
- Period
- 2021
- Total Revenue
- 14403.5
- Selling/ General/ Admin Expenses Total
- 5254.6
- Depreciation/ Amortization
- 669.6
- Other Operating Expenses Total
- 301
- Total Operating Expense
- 11873
- Operating Income
- 2530.5
- Net Income Before Taxes
- 2399.2
- Net Income
- 2133.6
- Diluted Normalized EPS
- 23.38
- Period
- 2021
- Total Assets
- 23884.7
- Total Liabilities
- 10892.4
- Total Equity
- 12992.3
- Tangible Book Valueper Share Common Eq
- 62.61
- Period
- 2021
- Cashfrom Operating Activities
- 3185.1
- Cashfrom Investing Activities
- -722.5
- Cashfrom Financing Activities
- -2548.9
- Net Changein Cash
- -90.5
- Period
- 2020
- Total Revenue
- 14253.1
- Selling/ General/ Admin Expenses Total
- 5142.8
- Depreciation/ Amortization
- 696.5
- Other Operating Expenses Total
- 804.3
- Total Operating Expense
- 12515.1
- Operating Income
- 1738
- Net Income Before Taxes
- 1495.4
- Net Income
- 1176.6
- Diluted Normalized EPS
- 14.4
- Period
- 2020
- Total Assets
- 23686.6
- Total Liabilities
- 13310.9
- Total Equity
- 10375.7
- Tangible Book Valueper Share Common Eq
- 35.14
- Period
- 2020
- Cashfrom Operating Activities
- 2505.4
- Cashfrom Investing Activities
- -1012.3
- Cashfrom Financing Activities
- -1094.2
- Net Changein Cash
- 398.9
- Period
- 2019
- Total Revenue
- 13165.6
- Selling/ General/ Admin Expenses Total
- 4287.6
- Depreciation/ Amortization
- 598.6
- Other Operating Expenses Total
- 592.2
- Total Operating Expense
- 10783.4
- Operating Income
- 2382.2
- Net Income Before Taxes
- 2382.1
- Net Income
- 1848.8
- Diluted Normalized EPS
- 18.12
- Period
- 2019
- Total Assets
- 23483.1
- Total Liabilities
- 13096.8
- Total Equity
- 10386.3
- Tangible Book Valueper Share Common Eq
- 32.51
- Period
- 2019
- Cashfrom Operating Activities
- 1543.2
- Cashfrom Investing Activities
- -4238.7
- Cashfrom Financing Activities
- 1884.6
- Net Changein Cash
- -810.9
- Period
- 2018
- Total Revenue
- 11954.4
- Selling/ General/ Admin Expenses Total
- 3850
- Depreciation/ Amortization
- 538.8
- Other Operating Expenses Total
- 467
- Total Operating Expense
- 9643.4
- Operating Income
- 2311
- Net Income Before Taxes
- 2330.8
- Net Income
- 1775.8
- Diluted Normalized EPS
- 17.65
- Period
- 2018
- Total Assets
- 18065.3
- Total Liabilities
- 9320.8
- Total Equity
- 8744.5
- Tangible Book Valueper Share Common Eq
- 59.37
- Period
- 2018
- Cashfrom Operating Activities
- 919.3
- Cashfrom Investing Activities
- -973.7
- Cashfrom Financing Activities
- 51.5
- Net Changein Cash
- -2.9
- Period
- 2017
- Total Revenue
- 9572.3
- Selling/ General/ Admin Expenses Total
- 3150.6
- Depreciation/ Amortization
- 373.3
- Other Operating Expenses Total
- 400.7
- Total Operating Expense
- 8040.7
- Operating Income
- 1531.6
- Net Income Before Taxes
- 1614.6
- Net Income
- 1487.7
- Diluted Normalized EPS
- 14.57
- Period
- 2017
- Total Assets
- 15220.7
- Total Liabilities
- 8260.7
- Total Equity
- 6960
- Tangible Book Valueper Share Common Eq
- 43.91
- Period
- 2017
- Cashfrom Operating Activities
- 1311.7
- Cashfrom Investing Activities
- -2871.9
- Cashfrom Financing Activities
- 2315.8
- Net Changein Cash
- 755.6
- Period
- 2022-09-30
- Total Revenue
- 4134.7
- Selling/ General/ Admin Expenses Total
- 671.7
- Depreciation/ Amortization
- 181.8
- Other Operating Expenses Total
- 1053.3
- Total Operating Expense
- 3501.2
- Operating Income
- 633.5
- Net Income Before Taxes
- 642.8
- Net Income
- 522.5
- Diluted Normalized EPS
- 5.1
- Period
- 2022-09-30
- Total Assets
- 25629.3
- Total Liabilities
- 8964.3
- Total Equity
- 16665
- Tangible Book Valueper Share Common Eq
- 100.38
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 1129.1
- Cashfrom Investing Activities
- -539.6
- Cashfrom Financing Activities
- -3063.8
- Net Changein Cash
- -2475.6
- Period
- 2022-06-30
- Total Revenue
- 4072.7
- Selling/ General/ Admin Expenses Total
- 681
- Depreciation/ Amortization
- 180.7
- Other Operating Expenses Total
- 1049.4
- Total Operating Expense
- 3423.3
- Operating Income
- 649.4
- Net Income Before Taxes
- 681
- Net Income
- 518.3
- Diluted Normalized EPS
- 5.16
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 3800
- Selling/ General/ Admin Expenses Total
- 546.7
- Depreciation/ Amortization
- 162.3
- Other Operating Expenses Total
- 1018.1
- Total Operating Expense
- 2959.5
- Operating Income
- 840.5
- Net Income Before Taxes
- 881
- Net Income
- 397.4
- Diluted Normalized EPS
- 4.88
- Period
- 2022-03-31
- Total Assets
- 27795.4
- Total Liabilities
- 10795.8
- Total Equity
- 16999.6
- Tangible Book Valueper Share Common Eq
- 102.64
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 2078.2
- Cashfrom Investing Activities
- 1154.4
- Cashfrom Financing Activities
- -868.3
- Net Changein Cash
- 2372.9
- Period
- 2021-12-31
- Total Revenue
- 3655
- Selling/ General/ Admin Expenses Total
- 585.5
- Depreciation/ Amortization
- 183.2
- Other Operating Expenses Total
- 969.7
- Total Operating Expense
- 3085.7
- Operating Income
- 569.3
- Net Income Before Taxes
- 599
- Net Income
- 500.4
- Diluted Normalized EPS
- 4.89
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 3759.8
- Selling/ General/ Admin Expenses Total
- 619.5
- Depreciation/ Amortization
- 177.3
- Other Operating Expenses Total
- 879.8
- Total Operating Expense
- 2924.9
- Operating Income
- 834.9
- Net Income Before Taxes
- 858.1
- Net Income
- 3002.3
- Diluted Normalized EPS
- 6.16
- Period
- 2021-09-30
- Total Assets
- 27471.2
- Total Liabilities
- 11282.9
- Total Equity
- 16188.3
- Tangible Book Valueper Share Common Eq
- 95.03
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 1187.6
- Cashfrom Investing Activities
- 1811.6
- Cashfrom Financing Activities
- -455.1
- Net Changein Cash
- 2545
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day408.16
- 10 Day401.89
- 20 Day414.26
- 50 Day409.82
- 100 Day389.37
- 300 Day374.26
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Torrent Pharmaceuticals
- 1604.4
- -13.7
- -0.85
- 1722.7
- 1235.88
- 54865.39
- Abbott India
- 20115.75
- 57.5
- 0.29
- 20895
- 15426.74
- 42887.25
- Zydus Lifesciences
- 409.9
- -3.2
- -0.77
- 487
- 319.4
- 42057.08
- Alkem Laboratories
- 3100.65
- -15.95
- -0.51
- 3784
- 2835
- 37237.92
- Lupin
- 765.9
- -4.2
- -0.55
- 972.5
- 583.05
- 35287.36
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Torrent Pharmaceuticals
- 50.59
- 9.22
- 16.36
- 10.81
- Abbott India
- 53.7
- 15.21
- 27.07
- 14.45
- Zydus Lifesciences
- 19.78
- 2.5
- 17
- 13.51
- Alkem Laboratories
- 22.64
- 4.31
- 18.92
- 14.07
- Lupin
- 147.39
- 2.9
- 0.08
- 0.13
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 74.98%
- 758,940,186
- Zydus Family Trust
- 74.96%
- 758,788,706
- Pripan Investment Private Limited
- 0%
- 17,821
- Pankaj Ramanbhai Patel
- 0%
- 44,553
- Pankaj Ramanbhai Patel HUF (Pankaj Ramanbhai Patel-Karta)
- 0%
- 29,702
- Sharvil Pankajbhai Patel
- 0%
- 14,851
- Taraben Patel Family Will Trust (Pankaj Ramanbhai Patel and Sharvil Pankajbhai Patel-Trustees)
- 0%
- 14,851
- Shivani Pankajbhai Patel
- 0%
- 14,851
- Pritiben Pankajbhai Patel
- 0%
- 14,851
- Public Shareholding
- 25.02%
- 253,263,953
- Llife Insurance Corporation of India
- 6.35%
- 64,267,147
- Others
- 0.95%
- 9,656,545
- Others
- 6.76%
- 68,441,694
- Kotak Flexicap Fund
- 2.5%
- 25,316,795
- Others
- 2.86%
- 28,972,573
- Others
- 2.6%
- 26,302,582
- Others
- 0.95%
- 9,644,173
- Others
- 0.84%
- 8,460,989
- HUF
- 0.22%
- 2,225,280
- Clearing Members
- 0.11%
- 1,102,913
- LLP
- 0.03%
- 287,557
- Trusts
- 0.02%
- 167,997
- Others
- 0.36%
- 3,641,523
- Others
- 0.17%
- 1,692,571
- Others
- 0.14%
- 1,466,296
- Others
- 0.07%
- 756,684
- Others
- 0.04%
- 378,412
- Others
- 0.02%
- 209,706
- Others
- 0.01%
- 101,475
- Others
- 0.01%
- 83,694
- Others
- 0.01%
- 65,546
- Others
- 0%
- 9,996
- Others
- 0%
- 8,613
- Others
- 0%
- 1,500
- Others
- 0%
- 1,391
- Others
- 0%
- 300
- Others
- 0%
- 1
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 11-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- 20-May-22
- Audited Results, Dividend & Buy Back
- 03-Feb-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- 11-Aug-21
- Quarterly Results
- 27-May-21
- Audited Results & Final Dividend
- 05-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 10-Aug-22
- 21-May-22
- AGM
- 18-Feb-22
- 25-Jan-22
- EGM
- 11-Aug-21
- 27-May-21
- AGM
- 11-Jun-21
- 18-May-21
- EGM
- -
- 20-May-22
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 20-May-22
- 29-Jul-22
- 28-Jul-22
- 2.5
- 27-May-21
- -
- 28-Jul-21
- 3.5
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Zydus Lifesciences
- Industry Biotechnology & Drugs
- ISIN INE010B01027
- BSE Code 532321
- NSE Code ZYDUSLIFE
Zydus Lifesciences Ltd., formerly Cadila Healthcare Limited, is an India-based life sciences company. The Company is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The Company has a pipeline for Biologics and Vaccines. The Company offers Lipaglyn to treat diabetic dyslipidemia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The Company in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The Company provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The Company has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.
MANAGEMENT
- Nitin Parekh Chief Financial Officer
- Dhaval Soni Company Secretary, Chief Compliance Officer
- Sharvil Patel Managing Director, Executive Director
- Ganesh Nayak Executive Director
Company Summary
ZYDUS LIFESCIENCES SUMMARY
Zydus Lifesciences is trading 0.77% lower at Rs 409.90 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 414.05 & 408.0. Zydus Lifesciences has given -14% in this year & 3.33% in the last 5 days.
Zydus Lifesciences has TTM P/E ratio 17.85 as compared to the sector P/E of 27.18. There are 30 analysts who have initiated coverage on Zydus Lifesciences. There are 4 analysts who have given it a strong buy rating & 10 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.
The company posted a net profit of 522.5 Crores in its last quarter.
Listed peers of Zydus Lifesciences include Torrent Pharmaceuticals (-0.85%), Abbott India (0.29%), Zydus Lifesciences (-0.77%) etc.
FAQs about Zydus Lifesciences
Zydus Lifesciences is trading at 409.90 as on 6 Dec, 2022 12:05:21 PM. This is -0.77% lower as compared to its previous closing price of 413.1
The market capitalization of Zydus Lifesciences is 42057.08 Cr as on 6 Dec, 2022 12:05:21 PM.
The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below -
- 2 analysts have given a strong sell rating
- 3 analysts have given a sell rating
- 11 analysts have given a hold rating
- 10 analysts have given a buy rating
- 4 analysts have given a strong buy rating
The 52 wk high for Zydus Lifesciences is 487.0 whereas the 52 wk low is 319.4
Zydus Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 17.85
- Sector P/E: 27.18
- Dividend Yield: 0.6%
- D/E ratio: -
Zydus Lifesciences reported a net profit of 4487.3 Cr in 2022.
